Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 8/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749261 | 0.89 | SMN1; SMN2 (0.49) | HPGDCYP1A2SMN1; SMN2PTGDR2TSHR | |
| SCHEMBL22816229 | 0.83 | PTGDR2 (0.49) | CYP2C9PPARGHPGDSMN1; SMN2CCR2 | |
| SCHEMBL1923196 | 0.81 | HPGD (0.48) | CYP2C9PPARGHPGDABCB11SMN1; SMN2 | |
| SCHEMBL22816013 | 0.80 | AKR1C3 (0.47) | KMOHPGDPTGDR2POLBMAPT | |
| SCHEMBL4330825 | 0.79 | SMN1; SMN2 (0.50) | HPGDCYP1A2SMN1; SMN2PTGDR2TSHR | |
| SCHEMBL3655553 | 0.78 | SCD (0.47) | HPGDSMN1; SMN2POLBMAPT | |
| SCHEMBL3744779 | 0.78 | SCD (0.40) | CYP2C9HPGDCYP1A2SMN1; SMN2POLB | |
| SCHEMBL1923628 | 0.76 | SMN1; SMN2 (0.52) | HPGDCYP1A2SMN1; SMN2PTGDR2TSHR | |
| SCHEMBL22815919 | 0.76 | ALOX15 (0.43) | CYP2C9PPARGHPGDCCR2POLB | |
| SCHEMBL22815640 | 0.75 | CCR2 (0.48) | HPGDCCR2PTGDR2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2207774-B1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225878-A1 | COMPOUNDS | BOUILLOT ANNE MARIE JEANNE (FR) | 2012-09-06 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207204-B2 | Triazole derivatives as SCD inhibitors | GLAXOSMITHKLINE LLC (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100297097-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC | 2010-11-25 | — | — | US | disclosed |
| WO-2009060054-A1 | TRIAZOLE DERIVATIVES AS SCD INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297097-A1 | COMPOUNDS | APP, BACE1, SCD | CYP2C9 309/4885PPARG 131/4885KMO 1039/4885 |
| US-20120225878-A1 | COMPOUNDS | CYP11B2, CYP11B1, SCD | CYP2C9 77/4885PPARG 388/4885KMO 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.